GaBI Journal

Aims & Scope

The scope of GaBI Journal is broad and of interest and relevance to professionals active in clinical practice, pharmaceutical science and policy.

Materials published in GaBI Journal include high quality research reports, literature reviews and case studies, all of which are peer reviewed.

Manuscripts on all aspects of generic and biosimilar medicines, covering areas in clinical, fundamental, technical, manufacturing, bi-processing, economic and social aspects of pharmaceuticals and therapeutics are welcome.

In addition, high quality work submitted in other formats, for example, scientific and evidence-based commentaries, may also be considered.

In all cases, the emphasis is on quality, originality and knowledge contribution to those involved in health care.

All manuscripts submitted to GaBI Journal are subject to a rigorous peer review process.

GaBI Journal plans to be indexed in PubMed within two years, and that indexing will be retrospective.

GaBI Journal is published quarterly from 2012.

All articles are published in English.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	0.2
2024	0.30

SJR (SCImago Journal Rank)

Year	Value
2024	0.150

Quartile

Year	Value
2024	Q3

h-index

Year	Value
2024	16

Journal Rank

Year	Value
2024	24529

Journal Citation Indicator

Year	Value
2024	19

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Health Professions and Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Saving money in the European healthcare systems with biosimilars

  Citation: 78

  Authors: Robert

• The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries─an overview

  Citation: 67

  Authors: Sabine

• Biologicals and biosimilars: a review of the science and its implications

  Citation: 63

  Authors: Paul J

• Norway, biosimilars in different funding systems. What works?

  Citation: 40

  Authors: Asbjørn

• A review of generic medicine pricing in Europe

  Citation: 38

  Authors: Steven

• Patent expiry dates for biologicals: 2018 update

  Citation: 34

  Authors:

• A review of patient perspectives on generics substitution: what are the challenges for optimal drug use

  Citation: 33

  Authors: Helle, Else-Lydia

• Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach

  Citation: 30

  Authors: Brian

• Pricing of oral generic cancer medicines in 25 European countries; findings and implications

  Citation: 29

  Authors: Brian, Andrew, Steven, Amanj, Jolanta, Antony P, Angela, Dzintars, Janet, Tomasz, Celia C, Iris, Admir, Christian, Robert, Wouter, Zornitza, Guenka, Ott, Catherine, Irene, Gisbert, John, Roberta, Arianit, Elita, Ieva, Patricia, JF (Hans), Vincent, Carolin, Anne Marthe, Robert, Magdalene, Vanda, Nataša, Tatjana, Ileana, Tanja, Mark, Jurij, Dominik, Mercè Obach, Corinne, Maria, Peter, Stuart, Alan

• ICH Q11: development and manufacture of drug substances–chemical and biotechnological/biological entities

  Citation: 27

  Authors: Keith

---